on the Mental Redition Capacity Act

Withholding and Withdrawing Life-prolonging Medical Treatment

Guidance for decision making

THIRD EDITION

British Medical Association



Withholding and Withdrawing Life-prolonging Medical Treatment

Guidance for decision making

THIRD EDITION

British Medical Association





© 2007 British Medical Association Published by Blackwell Publishing

BMJ Books is an imprint of the BMJ Publishing Group Limited, used under licence

Blackwell Publishing, Inc., 350 Main Street, Malden, Massachusetts 02148-5020, USA Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK Blackwell Publishing Asia Pty Ltd, 550 Swanston Street, Carlton, Victoria 3053, Australia

The right of the Author to be identified as the Author of this Work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

First published 1999 Second edition 2001 Third edition 2007

1 2007

ISBN: 978-1-4051-5957-9

Catalogue records for this title are available from the British Library and the Library of Congress

Set in 9.5/12 by Techbooks, India
Printed and bound in Singapore by COS Printers Pte Ltd

Commissioning Editor: Mary Banks Editorial Assistant: Vicki Pittman Development Editor: Charlie Hamlyn

Production Controller: Rachel Edwards

For further information on Blackwell Publishing, visit our website:

http://www.blackwellpublishing.com

The publisher's policy is to use permanent paper from mills that operate a sustainable forestry policy, and which has been manufactured from pulp processed using acid-free and elementary chlorine-free practices. Furthermore, the publisher ensures that the text paper and cover board used have met acceptable environmental accreditation standards.

Blackwell Publishing makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check that any product mentioned in this publication is used in accordance with the prescribing information prepared by the manufacturers. The author and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this book.

Withholding and Withdrawing Life-prolonging Medical Treatment

Guidance for decision making

Medical Ethics Committee

A publication from the BMA's Medical Ethics Committee (MEC) whose membership for 2006/07 was:

Professor Parveen Kumar President, BMA

Dr Michael Wilks* Chairman of the Representative Body,

BMA

Mr James Johnson Chairman of Council, BMA

Dr David Pickersgill Treasurer, BMA

Dr Anthony Calland Chairman, Medical Ethics Committee;

General Practitioner, Gwent

Dr Jonathan Brett Junior doctor, general practice,

Newcastle-upon-Tyne

Dr John Chisholm* General Practitioner, London
Dr Peter Dangerfield Medical Academic, Liverpool

Professor Bobbie Farsides* Professor of Medical Law and Ethics,

Brighton

Professor Ilora Finlay* Consultant in Palliative Medicine, Cardiff

Professor Robin Gill* Professor of Modern Theology,

Canterbury

Professor Raanan Gillon* General Practitioner; Professor of

Medical Ethics, London

Dr Evan Harris* Member of Parliament; former hospital

doctor, Oxford

Professor John Harris Sir David Alliance Professor of Bioethics,

Manchester

Professor Emily Jackson* Professor of Law, London
Dr Craig Knott House Officer, London

Dr Surendra Kumar General Practitioner, Widnes, Cheshire Professor Sheila McLean* Director of Institute of Law and Ethics,

Glasgow

Professor Jonathan Montgomery Professor of Health Care Law,

Southampton

Professor Ruud ter Meulen Professor of Ethics in Medicine, Bristol

Dr Peter Tiplady (deputy) Retired, East Cumbria

viii

Dr Frank Wells (deputy) Retired, Suffolk

Consultant Psychiatrist, London Dr Jan Wise Dr John Jenkins General Medical Council Observer Ms Jane O'Brien General Medical Council Observer Mr Chris Chaloner Royal College of Nursing Observer

^{*}Sub-group of the MEC to discuss this guidance

Editorial board for the third edition

Head of Medical Ethics: Ann Sommerville
Project Manager: Veronica English
Written by: Veronica English
Editorial Secretary: Patricia Fraser

Information about major developments since the publication of this guidance may be obtained from the BMA's website at: www.bma.org.uk/ethics or by contacting the Medical Ethics Department:

British Medical Association BMA House Tavistock Square London WC1H 9JP

Tel: 020 7383 6286 Fax: 020 7383 6233

Email: ethics@bma.org.uk

Acknowledgements for the third edition

We would like to thank those individuals and organisations who generously gave their time to review an earlier draft of this guidance. Whilst these contributions helped to inform the BMA's views, it should not be assumed that this guidance necessarily reflects the views of all those who contributed. We would particularly like to thank Anna Batchelor, Intensive Care Society; Beverley Taylor, Office of the Official Solicitor; Charlie McLaughlan, Royal College of Anaesthetists; Chris Chaloner, Royal College of Nursing; Donald Lyons, Mental Welfare Commission Scotland; Emma Wilbraham, Department of Health; Kathleen Glancy, Scottish Executive Health Department; Mike Hinchliffe, Children and Family Court Advisory and Support Service (CAFCASS); Ranald Macdonald, NHS Scotland Central Legal Office; Resuscitation Council (UK); Sandra McDonald, Office of the Public Guardian (Scotland); Sharon Burton and Roger Worthington, General Medical Council; Toby Williamson, Department for Constitutional Affairs.

Introduction

In medicine, decisions are made on a daily basis about the provision, with-holding or withdrawing of treatments, some of which could prolong life. Treatments which might provide a therapeutic benefit are not inevitably given but are weighed according to a number of factors, such as the patient's wishes, the treatment's invasiveness, side-effects, limits of efficacy and the resources available. The Intensive Care Society has estimated that approximately 50,000 patients are admitted to intensive care units in England and Wales each year. Of these, 30% (15,000 patients) die without leaving hospital, most as a result of active treatment being withdrawn [1].

Although not uncommon, few issues in medicine are more complex and difficult than those addressed by patients, their relatives and their doctors concerning the decision to withhold or withdraw potentially life-prolonging treatment. Technological developments continually extend the range of treatment options available to prolong life when organ or system failure would naturally result in death. Cardiopulmonary resuscitation, renal dialysis, artificial nutrition, hydration and ventilation prolong life and, in some cases, allow time for recovery but these techniques cannot, in themselves, reverse a patient's disease. Patients with progressive conditions such as motor neurone disease can have their lives prolonged by the application of technology, but their underlying illness cannot be cured and deterioration in their condition is unavoidable. The condition of other patients, for example those with very severe brain damage, may remain stable for many years if life-prolonging treatment is provided but they may have no hope of recovering more than very minimal levels of awareness of their surroundings. They may lack the ability to interact with others or capacity for self-awareness or self-directed action. In such severely damaged patients, interventions to prolong life by artificial means may fail to provide sufficient benefit to justify the burdens of intervention (see Section 9) and the proper course of action may be to withhold or withdraw further treatment.

Most people accept that treatment should not be prolonged indefinitely when it has ceased to provide a benefit for the patient. But patients and their families, doctors and other members of the clinical team and society as a whole need reassurance that individual decisions are carefully thought through, based on the best quality information available and follow a widely

agreed procedure. Decisions need to be made on an individual basis, assessing the particular circumstances, wishes and values of the patient to ensure that treatment is neither withdrawn too quickly nor unnecessarily prolonged. It is essential that there are clear, robust and transparent procedures for making these decisions. The BMA is very pleased to note that, over recent years, comprehensive guidance has been developed outlining the criteria and steps to be followed in making these decisions, particularly where difficult assessments are required about the best interests of incapacitated patients. In addition to the BMA's guidance, first published in 1999, there is now also detailed advice from the General Medical Council [2] and from the Royal College of Paediatrics and Child Health [3]. There is also statutory guidance for those providing treatment for adults who lack capacity, in the form of Codes of Practice under the Adults with Incapacity (Scotland) Act 2000 [4] and the Mental Capacity Act 2005 [5]. Nevertheless, there is only benefit in having guidance if it is available to, and used by, those responsible for making these decisions. Occasional media reporting has served to remind us that best practice is not yet universal and that we all have a responsibility to ensure that good communication and decision-making procedures are followed in all cases. In this document, the BMA seeks to provide a coherent and comprehensive set of principles which apply to all decisions to withhold or withdraw life-prolonging treatment. It is hoped that this general guidance will stimulate the development of accessible local policies and guidelines as part of a wider network of safeguards for doctors and patients.

The need for guidance in this area became clear from a wide-ranging consultation exercise undertaken by the BMA in 1998. This led to the first edition of this guidance being published in 1999. A second edition was published in 2001 to incorporate specific guidance on the impact of the Human Rights Act. This third edition includes subsequent developments in legislation specifically the Mental Capacity Act (which at the time of writing was due to come into force in 2007) – and the common law. Although these changes have clarified some aspects of the law, some legal uncertainties remain and judicial review will still be required in particular cases. Part of the aim of this guidance is to identify the type of cases where decisions may be made by the patient, the health care team and/or those close to the patient and those where a declaration from a court is required. This guidance does not set out to give definitive legal advice but to explain the legal and ethical principles that underpin decision making in this area and to help health professionals to recognise when further advice is needed. Of course, the law will not remain static and information about any major developments following publication will be posted on the BMA's website at www.bma.org.uk/ethics.

xiv Introduction

We hope that this guidance will give confidence to those required to make these difficult decisions and the families of those on whose behalf the decisions are made. The importance of good communication at all stages of the decision-making process cannot be overstated and this forms a central part of our guidance. At the time of writing the Mental Capacity Act 2005 was scheduled to come into force in two stages — in April and September 2007. For more information on the implementation of the Act, see the BMA's website at: www.bma.org.uk/ethics.

Contents

Medical Ethics Committee	viii
Editorial board for the third edition	Х
Acknowledgements for the third edition	xi
Introduction	xii
Part 1: How to use this guidance	1
1. Scope, purpose and structure of this guidance	1
Part 2: Defining key terms and concepts	3
2. The primary goal of medicine	3
3. Life-prolonging treatment	5
4. Capacity and incapacity	5
5. Duty of care	6
6. Quality of life	8
7. Benefit	10
8. Harm	11
9. Best interests	12
10. Futility	14
11. Basic care	15
12. Artificial nutrition and hydration	15
13. Oral nutrition and hydration	17
14. Foresight and intention	18
15. Withholding or withdrawing treatment	19
16. Conscientious objection	20
17. Resource management	21
Part 3: Legal and ethical considerations that apply	
to all decisions to withhold or withdraw treatment	23
18. Human Rights Act 1998	23
19. Fairness and non-discrimination	28
20. Communication	31
21. Confidentiality	32
22. Legal review	3.1

Part 4: Medical considerations that apply to all decisions to withhold or withdraw treatment	36
23. Medical assessment	36
24. Medical decision making	39
24. Medical decision making	37
Part 5: Decision making by adults with capacity	43
25. The law	43
26. Communication and information	47
Part 6: Decision making on behalf of adults who	
lack capacity	50
England and Wales	50
27. Patients with a Lasting Power of Attorney (LPA)	50
28. Patients with an advance decision about medical treatment	nent 52
29. Patients without a Lasting Power of Attorney or advanc	e
decision	57
30. Patients in persistent vegetative state (pvs)	61
Scotland	62
31. Patients with a welfare power of attorney or welfare gua	
32. Patients with an advance decision about medical treatment	
33. Patients without a welfare power of attorney or advance	3
decision	67
34. Patients in persistent vegetative state (pvs)	68
Northern Ireland	69
35. Patients with an advance decision about medical treatm	
36. Patients without an advance decision about medical treatment.	atment 69
37. Patients in persistent vegetative state (pvs)	71
All UK jurisdictions	72
38. Capacity and incapacity	72
39. Communication and information	73
40. Assessing best interests	77
41. Dealing with disagreement	80
Part 7: Decision making by young people with cap	acity 83
42. The law in England, Wales and Northern Ireland	83
43. The law in Scotland	88
44. Assessing capacity	91
45. Communicating with young people	92
46. Dealing with disagreement	95

Part 8: Decision making for children and	
young people who lack capacity	96
47. The law	96
48. Duties owed to babies and children	102
49. Communicating with parents	104
50. Assessing best interests	106
51. Dealing with disagreement	108
Part 9: Once a decision has been reached	109
52. Keeping others informed	109
53. Recording and reviewing the decision	109
54. Providing support	111
55. Respecting patients' wishes after death	113
Appendix 1 Useful addresses	114
References	118
Index	123

Part 1 How to use this guidance

1. Scope, purpose and structure of this guidance

1.1. This document covers a wide range of different scenarios, treatments, patients and UK jurisdictions. With this in mind some parts of the guidance cover the general moral, legal and practical issues that apply to all decisions while other sections provide more specific information enabling readers to quickly identify the information they need.

We recommend that Parts 2, 3 and 4 of this guidance be read first as they set the scene for decision making, define the concepts and definitions used throughout and address the practical considerations that apply to all decisions. From Part 5 onwards the guidance is divided up into sections based on whether the patient is an adult who has or lacks capacity or a child or young person who has or lacks capacity. Clearly there is overlap and some repetition is inevitable but cross-referencing is used wherever possible. Although we have tried to give a clear indication of the important factors to consider with each type of patient, information that is provided in other sections may also be helpful in giving an overall picture of the decision-making process.

Summary boxes have been included throughout the text to ease navigation through the guidance and legal cases are summarised to illustrate the relevant legal points. Although some of these cases are now quite old and were decided before the Human Rights Act and mental capacity legislation came into force, they remain important in guiding both legal and medical practice.

This guidance is intended to complement, and not replace, statutory guidance issued under mental capacity legislation. It is essential that all health professionals, who are working in England, Wales and Scotland with adults who lack capacity, are familiar with the statutory Codes of Practice published under the Mental Capacity Act 2005 and the Adults with Incapacity (Scotland) Act 2000.

1.2. The main focus of this guidance is decisions to withdraw or withhold life-prolonging treatment from patients who are likely to live for weeks, months or possibly years, if treatment is provided but who, without treatment, will or may die earlier. In some areas mention is also made of treatment decisions for those patients whose imminent death is inevitable.

2 How to use this guidance

This guidance focuses on the process through which decisions are made to withdraw or withhold life-prolonging treatment from all types of patients - adults with capacity, adults lacking capacity, young people with capacity and children and young people who lack capacity. Such decisions are taken on a regular basis, throughout the country where, for example, patients with capacity decide that, for them, the burdens of further aggressive chemotherapy or dialysis outweigh the potential benefits. Or, where patients lack capacity, it is judged that invasive treatment would not be in their best interests because it is unable to provide a level of recovery that would justify the intervention. Similarly, a decision may be made that, in the event of cardiac arrest, a patient should not be subjected to cardiopulmonary resuscitation because the chances of recovery, or the level of recovery that could reasonably be expected, would not provide a net benefit to that patient. These decisions are always profound and cannot be taken lightly. The intention of this guidance is to set down established good practice in this area to help all those involved with making such decisions.

1.3. This document is not an attempt to define rules which must be followed. Rather, it provides general guidance about the principles and factors to take into account in reaching a decision.

This guidance does not provide a simple set of instructions to be followed without reflection but a tool to inform and aid decision making; it does not provide easy answers but offers an approach through which an appropriate decision may be reached. It reflects the standards that doctors must meet, as required by law and set out by the General Medical Council, and sets these standards within a broader context with a view to providing practical advice for decision making. Although principally aimed at health professionals, others who are responsible for decision making, such as the parents of young children and those who are appointed as personal welfare attorneys or deputies for incapacitated adults, may also find this guidance useful. This document provides a basis for discussion between all those involved in making decisions, which will include health professionals, the patient and those close to or representing the patient.

Part 2 Defining key terms and concepts

This section defines some of the key terms and concepts that are used throughout this document. It is useful to read through this section to provide general information about, and set the scene for, decision making before moving on to the more specific information provided in later sections. In order to minimise repetition these definitions are not repeated later in the text and so it is also necessary to refer back to these definitions when reading later sections of the guidance.

2. The primary goal of medicine

2.1. The primary goal of medical treatment is to benefit the patient by restoring or maintaining the patient's health as far as possible, maximising benefit and minimising harm. If a patient with capacity has refused the treatment or if the patient lacks capacity and the treatment would fail or ceases to provide a net benefit to the patient, then that goal cannot be realised and the treatment should, ethically and legally, be withheld or withdrawn. Good quality care and palliation of symptoms should, however, continue.

Health care is normally based on the common sense assumption that life-prolonging treatment is beneficial and that most patients would want it. In the majority of cases, therefore, it is provided unless the patient refuses it or the patient's death is imminent and inevitable. There are, however, some extreme cases where life-prolonging treatment fails to provide a net benefit to the patient because it is unable to achieve a level of recovery that justifies the corresponding burdens of the treatment. Or, the treatment may keep the patient alive but be unable to stop the progression of the disease or provide any hope of the patient recovering self-awareness, awareness of others and the ability to intentionally interact with them (see Section 9). Patients sometimes decide that the stage has been reached beyond which, for them, continued treatment aimed at prolonging life, although possible, would be inappropriate. Where patients lack capacity, these decisions must be taken in a way that reflects their wishes or, if these are not known, their best interests. This may include a decision not to provide or continue to provide an intervention